{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Columbus",
      "state": "OH",
      "country": "United States",
      "classification": "Class III",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "75581",
      "recalling_firm": "Amerisource Health Services",
      "address_1": "2550 John Glenn Ave Ste A",
      "address_2": "N/A",
      "postal_code": "43217-1188",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide and Puerto Rico",
      "recall_number": "D-0137-2017",
      "product_description": "Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",
      "product_quantity": "a) 15,409 bottles b) 5,128 bottles",
      "reason_for_recall": "Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.",
      "recall_initiation_date": "20161027",
      "center_classification_date": "20161116",
      "termination_date": "20170629",
      "report_date": "20161123",
      "code_info": "Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018."
    }
  ]
}